Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2023 | Repurposing monoclonal antibodies to manage CAR-T therapy toxicities

Monia Marchetti • 26 Apr 2023
EBMT 2023
General Anakinra Antibodies Siltuximab

Monia Marchetti, MD, Azienda Ospedaliera SS. Antonio e. Biagio e Cesare Arrigo, Alessandria, Italy, comments on the morbidity associated with CAR-T therapy, highlighting that a therapeutic potential exists in the repurposing of monoclonal antibodies such as anakinra or siltuximab in the management of post-CAR-T toxicity. This interview took place at the 49th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) held in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Gilead consultancy fees.

More from Monia Marchetti

2:46
Challenges in selecting patients with MF for SCT & using AI to determine the optimal timing for SCT
Monia Marchetti • 26 Apr 2023
2:25
Key EBMT guideline updates for the treatment and prophylaxis of GvHD
Monia Marchetti • 26 Apr 2023
2:50
Assessing the cost-effectiveness of CAR-T therapy in adult patients with R/R ALL
Monia Marchetti • 26 Apr 2023

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals